RA
CSTL icon

Royce & Associates’s Castle Biosciences CSTL Stock Holding History

Royce & Associates’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,365
Closed -$334K – 872
2024
Q2 		$334K Buy
15,365
+4,240
+38% +$94.5K ﹤0.01% 818
2024
Q1 		$246K Sell
11,125
-20,517
-65% -$446K ﹤0.01% 821
2023
Q4 		$683K Buy
31,642
+8,833
+39% +$155K 0.01% 768
2023
Q3 		$385K Buy
+22,809
New +$399K ﹤0.01% 833
2021
Q1 		– Sell
-35,000
Closed -$2.35M – 1021
2020
Q4 		$2.35M Sell
35,000
-481
-1% -$26.1K 0.02% 693
2020
Q3 		$1.82M Buy
35,481
+6,481
+22% +$288K 0.02% 695
2020
Q2 		$1.09M Buy
+29,000
New +$991K 0.01% 761

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Royce & Associates's CSTL Position: Q3 2024 in Review

Royce & Associates sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 15,365 shares — an estimated $334K sold.

Royce & Associates first reported a position in CSTL in Q2 2020 and held it in 7 quarters. The position peaked at $2.35M in Q4 2020. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Royce & Associates reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 15,365 Castle Biosciences shares in Q3 2024, an estimated $334K.
  • Royce & Associates first reported a position in Castle Biosciences in Q2 2020 and held it in 7 quarters.
  • Royce & Associates's Castle Biosciences position peaked at $2.35M in Q4 2020.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.